Expanding the Genetic and Clinical Spectrum of SCN1A-Related Hemiplegic Migraine: Analysis of Mutations in Japanese
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041426 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Daisuke Danno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Headache Center, Department of Neurology, Tominaga Hospital Japan, Osaka 556-0017, Japan. Hauptthemen laut MEDLINE: Migraine with Aura, Mutation, NAV1.1 Voltage-Gated Sodium Channel, East Asian People. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Abstract (Originalsprache)
Familial hemiplegic migraine (FHM) is characterized by repeated episodes of reversible localized neurological deficits, in addition to headache. The aura of HM includes visual, sensory, motor, and verbal symptoms. Hemiplegic migraine (HM) is classified into non-familial sporadic HM (SHM) and familial HM (FHM). Here, we analyzed the clinical symptoms and their relevance in four Japanese patients considered to have SCN1A mutations as a cause. Sequencing of SCN1A was performed using a whole exome sequence method in 48 blood samples from clinically suspected patients with FHM. Subsequently, algorithm analysis, allele frequency determination, and three-dimensional structure analysis of the recognized variants were performed, and the recognized variants were evaluated. We found five heterozygous missense mutations (p.A23E, p.V250L, p.T398M, p.R1575C, p.L1660I) in SCN1A, three of which had not been reported. These five mutations may also affect the structure of the protein products, as assessed using a three-dimensional structural analysis. In all cases, the clinical symptoms included visual, sensory, motor, and verbal symptoms, which are forms of aura. Similarities were detected, such as the appearance of symptoms at a young age and other symptoms, such as hemiplegia after a headache attack. We report five missense mutations in SCN1A of Japanese cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache Center, Department of Neurology, Tominaga Hospital Japan, Osaka 556-0017, Japan.
- Department of Life Science, Faculty of Science and Engineering, Kindai University, Osaka 577-8502, Japan.
- Department of Clinical Genetics, Kindai University Hospital Japan, Osaka 589-8511, Japan.
- Department of Neurology, Faculty of Medicine, Kindai University, Osaka 589-8511, Japan.
- Department of Neurology, Konan Medical Center, Kobe 658-0064, Japan.
ORCID-Profile: Makoto Samukawa, Keisuke Yoshikawa, Yoshitaka Nagai, Takao Takeshima
Förderung
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
Zitieren
APA
Danno, D., Tada, H., Oda, I., Kawashita, N., Hirano, M., Kitamura, S., Kikui, S., Samukawa, M., Yoshikawa, K., Mitsui, Y., Nagai, Y., Takeshima, T., & Saigoh, K. (2025). Expanding the Genetic and Clinical Spectrum of SCN1A-Related Hemiplegic Migraine: Analysis of Mutations in Japanese. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041426
Vancouver
Danno D, Tada H, Oda I, Kawashita N, Hirano M, Kitamura S, et al. Expanding the Genetic and Clinical Spectrum of SCN1A-Related Hemiplegic Migraine: Analysis of Mutations in Japanese. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041426
BibTeX
@article{Danno2025,
author = {Danno, Daisuke and Tada, Haruka and Oda, Itsuki and Kawashita, Norihito and Hirano, Makito and Kitamura, Shigekazu and Kikui, Shoji and Samukawa, Makoto and Yoshikawa, Keisuke and Mitsui, Yoshiyuki and Nagai, Yoshitaka and Takeshima, Takao and Saigoh, Kazumasa},
title = {Expanding the Genetic and Clinical Spectrum of SCN1A-Related Hemiplegic Migraine: Analysis of Mutations in Japanese},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041426}
}
EUVIMED